For research use only. Not for therapeutic Use.
Ziftomenib (Cat No.: I038695) is a potent, selective inhibitor of the menin–KMT2A (MLL) protein–protein interaction, designed to disrupt oncogenic transcriptional programs in acute leukemias. By blocking menin binding to KMT2A fusion proteins, ziftomenib downregulates HOX gene expression and promotes differentiation of leukemic cells. It has shown clinical potential in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with KMT2A rearrangements or NPM1 mutations. Ziftomenib represents a targeted epigenetic therapy aimed at genetically defined subtypes of hematologic malignancies, currently under clinical investigation.
| CAS Number | 2134675-36-6 |
| Synonyms | 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile |
| Molecular Formula | C33H42F3N9O2S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1 |
| InChIKey | BGGALFIXXQOTPY-NRFANRHFSA-N |
| SMILES | CC1=C(C=CC2=C1C=C(N2CC(C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F |
| Reference | [1]. Tao Wu, et al. Substituted inhibitors of menin-mll and methods of use. WO2017161028A1. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
